Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Alfresa to Train MSs to Help Boost Profits, Cut Costs
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- BUSINESS NEWS IN BRIEF
February 21, 2005
- MEDICAL DEVICE NEWS IN BRIEF
February 21, 2005
- Alliance with PPD Enables Us to Meet Various Needs of Clients: Ms Oishi of CMIC
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- Nippon Kayaku to Increase Focus on Oncology
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 2/3 of Ethical Drugs Designated as "Rx-only Drugs"
February 21, 2005
- Korosho to Demand PIII Data in NDA for Anticancer Agents
February 21, 2005
- Handling of Applications for Add'l Indications of Anticancer Drugs Notified
February 21, 2005
- Add. Indications Approved for 45 Drugs Used Off-label: JAPIC Seminar
February 21, 2005
- REGULATORY NEWS IN BRIEF
February 21, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 21, 2005
- MONITOR
February 21, 2005
- Aiming at Acquiring "Absolute No.1" in Diagnostic Market: Mr Ogawa of RDKK
February 21, 2005
- The Society of Japanese Pharmacopoeia Seminar
February 21, 2005
- 1st 3Qtrs Business Results -1-
February 14, 2005
- 1st 3Qtrs Business Results -2-
February 14, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…